TABLE 1.
Clinical and biochemical characteristics of the 81 subjects enrolled at baseline
| Placebo (n = 20) | Atorvastatin (n = 22) | Evolocumab (n = 20) | Evolocumab/Atorvastatin (n = 19) | |
|---|---|---|---|---|
| Age (years) | 32.9 (27.8–39.1) | 29.7 (26.6–33.1) | 32.2 (27.2–38.1) | 30.1 (26.1–34.6) |
| Body mass index (kg/m2) | 24.6 (23.2–26.0) | 24.9 (23.7–26.2) | 24.6 (23.7–25.6) | 25.6 (24.2–27.2) |
| SBP (mmHg) | 127 (124–130) | 123 (119–127) | 124 (120–129) | 124 (118–130) |
| DBP (mmHg) | 78.3 (75.0–81.7) | 76.5 (72.7–80.6) | 74.2 (67.8–81.2) | 76.3 (72.3–80.6) |
| Glucose (mmol/L) | 5.23 (5.06–5.41) | 5.31 (5.16–5.47) | 5.35 (5.11–5.60) | 5.39 (5.24–5.55) |
| Total cholesterol (mmol/L) | 4.57 (4.40–4.76) | 4.69 (4.43–4.97) | 4.52 (4.23–4.83) | 4.60 (4.21–5.02) |
| Triglycerides (mmol/L) | 0.82 (0.75–0.90) | 0.90 (0.79–1.04) | 0.80 (0.67–0.96) | 0.94 (0.77–1.15) |
| HDL‐cholesterol (mmol/L) | 1.17 (1.06–1.30) | 1.22 (1.12–1.33) | 1.11 (0.98–1.25) | 1.14 (1.01–1.28) |
| LDL‐cholesterol (mmol/L) | 3.05 (2.89–3.22) | 3.09 (2.89–3.31) | 3.04 (2.84–3.26) | 2.99 (2.71–3.29) |
| ApoB, g/L | 0.84 (0.79–0.89) | 0.84 (0.79–0.89) | 0.84 (0.79–0.90) | 0.85 (0.78–0.94) |
| VLDL‐apoB, mg/L | 41.7 (34.3–50.7) | 47.0 (37.8–58.5) | 46.9 (34.8–63.2) | 53.0 (40.3–69.5) |
| IDL‐apoB, mg/L | 32.7 (28.4–37.7) | 33.2 (28.5–38.9) | 36.5 (29.2–45.7) | 40.9 (33.5–50.0) |
| LDL‐apoB, mg/L | 465 (411–527) | 431 (378–492) | 447 (369–541) | 456 (391–533) |
| Lipoprotein (a), nmol/L | 23.2 (12.0–45.1) | 11.7 (7.33–18.7) | 19.9 (10.3–38.3) | 20.9 (10.9–40.0) |
Values expressed as geometric mean (95% CI).
Abbreviations: Apo, apolipoprotein; CI, confidence interval; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure.